Edition:
United Kingdom

Jiangsu Hengrui Medicine Co Ltd (600276.SS)

600276.SS on Shanghai Stock Exchange

67.58CNY
15 Dec 2017
Change (% chg)

¥-2.06 (-2.96%)
Prev Close
¥69.64
Open
¥69.60
Day's High
¥69.60
Day's Low
¥67.49
Volume
10,817,990
Avg. Vol
11,077,257
52-wk High
¥76.92
52-wk Low
¥37.25

Select another date:

Wed, Nov 29 2017

BRIEF-Jiangsu Hengrui Medicine passes U.S. FDA approval

* Says it received FDA approval for Dexmedetomidine Hydrochloride Injection from U.S. Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine gets approval for clinical trials of drugs

* Says it gets clinical trials approval for its drug named Seebri® Breezhaler® from China Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine's 9-month net profit up 20.7 pct y/y

* Says 9-month net profit up 20.7 percent y/y at 2.3 billion yuan ($347.33 million)

BRIEF-Jiangsu Hengrui Medicine passes FDA approval

* Says it received approval for its cisatracurium besilate injection from U.S Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine's H1 net profit up 19.7 pct y/y

* Says H1 net profit up 19.7 percent y/y at 1.6 billion yuan ($242.26 million)

BRIEF-Jiangsu Hengrui Medicine and unit plans clinical trail for new drug SHR0302

* Says it and unit plans to start clinical trail for new drug SHR0302, which is a kind of selective depressant used for treatment of rheumatoid arthritis

BRIEF-Jiangsu Hengrui Medicine passes U.S. FDA approval

* Says it received FDA approval for Docetaxel Injection from U.S Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine's main product enters into National health insurance's list

* Says its main product ApatinibMesylate Tablets, a oral absorption, has been listed on National health insurance's list

Select another date: